|
US10130697B2
(en)
|
2010-03-23 |
2018-11-20 |
Wisconsin Alumni Research Foundation (Warf) |
Vaccines comprising mutant attenuated influenza viruses
|
|
ES2655051T3
(es)
|
2011-08-26 |
2018-02-16 |
Wisconsin Alumni Research Foundation |
Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas
|
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
US10053671B2
(en)
|
2014-06-20 |
2018-08-21 |
Wisconsin Alumni Research Foundation (Warf) |
Mutations that confer genetic stability to additional genes in influenza viruses
|
|
AR102198A1
(es)
|
2014-10-09 |
2017-02-08 |
Regeneron Pharma |
Proceso para reducir partículas subvisibles en una formulación farmacéutica
|
|
TWI710573B
(zh)
|
2015-01-26 |
2020-11-21 |
美商再生元醫藥公司 |
抗伊波拉病毒醣蛋白之人類抗體
|
|
TWI899515B
(zh)
|
2015-08-04 |
2025-10-01 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
|
AU2017221444B2
(en)
|
2016-02-19 |
2021-07-29 |
Wisconsin Alumni Research Foundation (Warf) |
Improved influenza B virus replication for vaccine development
|
|
US11542332B2
(en)
|
2016-03-26 |
2023-01-03 |
Bioatla, Inc. |
Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
WO2018017964A2
(en)
|
2016-07-21 |
2018-01-25 |
Emory University |
Ebola virus antibodies and binding agents derived therefrom
|
|
MX2019000935A
(es)
|
2016-08-16 |
2019-07-04 |
Regeneron Pharma |
Metodos para cuantificar anticuerpos individuales de una mezcla.
|
|
WO2018039499A1
(en)
|
2016-08-24 |
2018-03-01 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
|
IL312194B1
(en)
|
2016-10-25 |
2026-01-01 |
Regeneron Pharma |
Methods and systems for analyzing chromatography data
|
|
CN113512111B
(zh)
*
|
2017-03-10 |
2023-08-15 |
北京天广实生物技术股份有限公司 |
抗埃博拉病毒单克隆抗体、其制备方法及用途
|
|
CN114075269A
(zh)
|
2017-07-06 |
2022-02-22 |
菲仕兰坎皮纳荷兰私人有限公司 |
用于制备糖蛋白的细胞培养工艺
|
|
US12162925B2
(en)
*
|
2017-09-15 |
2024-12-10 |
The Wistar Institute Of Anatomy And Biology |
DNA-encoded monoclonal antibodies targeting the Ebolavirus glycoprotein
|
|
MX2020002850A
(es)
|
2017-09-19 |
2020-07-24 |
Regeneron Pharma |
Metodos para reducir la formacion de particulas y composiciones formadas a partir de estas.
|
|
US11197926B2
(en)
|
2017-10-25 |
2021-12-14 |
Wisconsin Alumni Research Foundation (Warf) |
Recombinant influenza viruses with stabilized HA for replication in eggs
|
|
RU2686630C1
(ru)
*
|
2017-12-22 |
2019-04-29 |
федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации |
Штаммы гибридных клеток животных Mus. Musculus - продуценты моноклональных антител к белку GP вируса Эбола (subtype Zaire) и моноклональные антитела к белку GP вируса Эбола (subtype Zaire)
|
|
CN111479618B
(zh)
|
2017-12-22 |
2022-08-02 |
瑞泽恩制药公司 |
用于表征药物产品杂质的系统和方法
|
|
EP3724223A1
(en)
*
|
2018-01-02 |
2020-10-21 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
|
KR20200115485A
(ko)
|
2018-01-31 |
2020-10-07 |
리제너론 파마슈티칼스 인코포레이티드 |
약물 생성물 불순물을 특성화하기 위한 시스템 및 방법
|
|
US20210047388A1
(en)
*
|
2018-01-31 |
2021-02-18 |
The Wistar Institute Of Anatomy And Biology |
Nucleic acid antibody constructs for use against ebola virus
|
|
TWI786265B
(zh)
|
2018-02-02 |
2022-12-11 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
|
US12460270B2
(en)
|
2018-02-28 |
2025-11-04 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for identifying viral contaminants
|
|
CN108373500A
(zh)
*
|
2018-03-12 |
2018-08-07 |
中国科学院微生物研究所 |
一种热稳定性埃博拉治疗性抗体的制备及应用
|
|
US12253490B2
(en)
|
2018-03-19 |
2025-03-18 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
US12259355B2
(en)
|
2018-03-19 |
2025-03-25 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
BR112020015291B1
(pt)
|
2018-03-19 |
2023-09-26 |
Regeneron Pharmaceuticals, Inc |
Tampão de amostra de eletroforese aquoso, método para identificar contaminantes ou impurezas em uma amostra de fármaco proteico, e, kit
|
|
SG11202008848XA
(en)
*
|
2018-03-26 |
2020-10-29 |
Regeneron Pharma |
Anti-pfrh5 antibodies and antigen-binding fragments thereof
|
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
TWI853823B
(zh)
|
2018-07-02 |
2024-09-01 |
美商里珍納龍藥品有限公司 |
自混合物製備多肽之系統及方法
|
|
WO2020014443A1
(en)
*
|
2018-07-12 |
2020-01-16 |
Vanderbilt University |
Pan-ebolavirus neutralizing human antibodies and methods of use therefor
|
|
US12343390B2
(en)
|
2018-08-07 |
2025-07-01 |
Wisconsin Alumni Research Foundation (Warf) |
Recombinant biologically contained filovirus vaccine
|
|
US11389523B2
(en)
|
2018-08-20 |
2022-07-19 |
Wisconsin Alumni Research Foundation (Warf) |
Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
|
|
CN112218877B
(zh)
|
2018-08-27 |
2025-07-25 |
瑞泽恩制药公司 |
拉曼光谱在下游纯化中的应用
|
|
KR20210053816A
(ko)
|
2018-08-30 |
2021-05-12 |
리제너론 파마슈티칼스 인코포레이티드 |
단백질 복합체를 특성화하기 위한 방법
|
|
CN111138528B
(zh)
*
|
2018-11-06 |
2021-07-30 |
中国人民解放军军事科学院军事医学研究院 |
特异性结合于埃博拉病毒糖蛋白聚糖帽的单克隆抗体5a8
|
|
CN111138531B
(zh)
*
|
2018-11-06 |
2021-07-30 |
中国人民解放军军事科学院军事医学研究院 |
特异结合于ebov的gp1亚基的单克隆抗体8f9及应用
|
|
CN111138527B
(zh)
*
|
2018-11-06 |
2021-07-30 |
中国人民解放军军事科学院军事医学研究院 |
抗埃博拉病毒糖蛋白gp1亚基的单克隆抗体4f1及应用
|
|
CN111138526B
(zh)
|
2018-11-06 |
2021-07-30 |
中国人民解放军军事科学院军事医学研究院 |
一种抗埃博拉病毒糖蛋白gp2亚基的单克隆抗体2g1及应用
|
|
IL284471B2
(en)
|
2019-01-16 |
2025-01-01 |
Regeneron Pharma |
Methods for identifying free thiols in proteins
|
|
CN113874496A
(zh)
|
2019-02-08 |
2021-12-31 |
威斯康星校友研究基金会(Warf) |
人源化细胞系
|
|
WO2020223699A1
(en)
|
2019-05-01 |
2020-11-05 |
Wisconsin Alumni Research Foundation (Warf) |
Improved influenza virus replication for vaccine development
|
|
EP3969908A1
(en)
|
2019-05-13 |
2022-03-23 |
Regeneron Pharmaceuticals, Inc. |
Improved competitive ligand binding assays
|
|
JP7627911B2
(ja)
|
2019-08-27 |
2025-02-07 |
ウィスコンシン アルムニ リサーチ ファンデイション |
卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス
|
|
US12297451B1
(en)
|
2019-10-25 |
2025-05-13 |
Regeneron Pharmaceuticals, Inc. |
Cell culture medium
|
|
JP6761889B1
(ja)
*
|
2019-11-11 |
2020-09-30 |
株式会社Ｇｓｐエンタープライズ |
抗ヒトＣｒｉｐｔｏ−１抗体
|
|
MX2022006236A
(es)
|
2019-11-25 |
2022-06-22 |
Regeneron Pharma |
Formulaciones de liberacion sostenida con emulsiones no acuosas.
|
|
GB201917480D0
(en)
*
|
2019-11-29 |
2020-01-15 |
Univ Oxford Innovation Ltd |
Antibodies
|
|
KR102544013B1
(ko)
|
2020-01-21 |
2023-06-19 |
리제너론 파마슈티칼스 인코포레이티드 |
당질화된 단백질의 전기영동을 위한 탈당질화 방법
|
|
EP4093435A1
(en)
|
2020-01-24 |
2022-11-30 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
KR20210095781A
(ko)
|
2020-01-24 |
2021-08-03 |
주식회사 에이프릴바이오 |
항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
|
|
WO2021150874A1
(en)
|
2020-01-24 |
2021-07-29 |
Wisconsin Alumni Research Foundation (Warf) |
Recombinant influenza viruses with stabilized na
|
|
EP3872091B1
(en)
|
2020-02-26 |
2023-06-14 |
VIR Biotechnology, Inc. |
Antibodies against sars-cov-2
|
|
WO2021195410A1
(en)
|
2020-03-25 |
2021-09-30 |
Wisconsin Alumni Research Foundation (Warf) |
Recombinant multivalent influenza viruses
|
|
KR20240038138A
(ko)
*
|
2020-07-13 |
2024-03-22 |
리제너론 파마슈티칼스 인코포레이티드 |
단백질에서 글루타민 잔기에 접합된 캄토테신 유사체 및 그의 용도
|
|
CA3192999A1
(en)
|
2020-08-31 |
2022-03-03 |
Regeneron Pharmaceuticals, Inc. |
Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
|
|
WO2022074630A1
(en)
*
|
2020-10-09 |
2022-04-14 |
Auxilla Pharmaceuticals And Research Llp |
Liquid oral suspension of favipiravir
|
|
EP4251128A1
(en)
|
2020-11-25 |
2023-10-04 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous membrane emulsification
|
|
WO2022133135A1
(en)
|
2020-12-17 |
2022-06-23 |
Regeneron Pharmaceuticals, Inc. |
Fabrication of protein-encapsulating microgels
|
|
TW202241497A
(zh)
*
|
2021-01-05 |
2022-11-01 |
美商伊米若梅有限公司 |
針對SARS-CoV-2棘蛋白之抗體雞尾酒療法
|
|
CN116761880A
(zh)
|
2021-01-20 |
2023-09-15 |
瑞泽恩制药公司 |
改进细胞培养物中的蛋白质滴度的方法
|
|
CA3207883A1
(en)
|
2021-03-03 |
2022-09-09 |
Xiaobin Xu |
Systems and methods for quantifying and modifying protein viscosity
|
|
AU2022286340A1
(en)
|
2021-06-01 |
2024-01-04 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
WO2023039457A1
(en)
|
2021-09-08 |
2023-03-16 |
Regeneron Pharmaceuticals, Inc. |
A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins
|
|
AU2022348521A1
(en)
|
2021-09-20 |
2024-04-04 |
Regeneron Pharmaceuticals, Inc. |
Methods of controlling antibody heterogeneity
|
|
CN118076894A
(zh)
|
2021-10-07 |
2024-05-24 |
里珍纳龙药品有限公司 |
pH建模和控制的系统及方法
|
|
KR20240090312A
(ko)
|
2021-10-07 |
2024-06-21 |
리제너론 파아마슈티컬스, 인크. |
Ph 미터 보정 및 교정
|
|
KR20240097864A
(ko)
|
2021-10-26 |
2024-06-27 |
리제너론 파마슈티칼스 인코포레이티드 |
상이한 온도에서 실험실 용수를 생성하고 실험실 용수를 분배하는 시스템 및 방법
|
|
AU2023208050A1
(en)
|
2022-01-14 |
2024-07-04 |
Regeneron Pharmaceuticals, Inc. |
Verrucarin a derivatives and antibody drug conjugates thereof
|
|
US20240245779A1
(en)
|
2023-01-25 |
2024-07-25 |
Regeneron Pharmaceuticals, Inc. |
Methods of modeling liquid protein composition stability
|
|
TW202445126A
(zh)
|
2023-01-25 |
2024-11-16 |
美商再生元醫藥公司 |
基於質譜法之體內共表現抗體之表徵
|
|
TW202445138A
(zh)
|
2023-02-01 |
2024-11-16 |
美商再生元醫藥公司 |
用於生物巨分子分析之具質譜法的不對稱流場流分離
|
|
WO2024178213A2
(en)
|
2023-02-22 |
2024-08-29 |
Regeneron Pharmaceuticals, Inc. |
System suitability parameters and column aging
|
|
TW202508625A
(zh)
|
2023-05-01 |
2025-03-01 |
美商再生元醫藥公司 |
使用苯酚或苯甲醇之多劑量抗體藥物產品
|
|
US20250109905A1
(en)
|
2023-09-29 |
2025-04-03 |
Regeneron Pharmaceuticals, Inc. |
Lyophilization using controlled nucleation
|
|
US20250129117A1
(en)
|
2023-10-18 |
2025-04-24 |
Regeneron Pharmaceuticals, Inc. |
Rapid purification of monoclonal antibody from in-process upstream cell culture material
|
|
US20250145662A1
(en)
|
2023-11-02 |
2025-05-08 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing lipase activity using stress
|
|
WO2025166281A1
(en)
|
2024-02-01 |
2025-08-07 |
Regeneron Pharmaceuticals, Inc. |
Platform for charge-detection mass spectrometry analysis of aavs
|
|
WO2025175164A1
(en)
|
2024-02-16 |
2025-08-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
|
|
WO2025194043A1
(en)
|
2024-03-15 |
2025-09-18 |
Regeneron Pharmaceuticals, Inc. |
Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
|
|
WO2026025028A1
(en)
|
2024-07-26 |
2026-01-29 |
Regeneron Pharmaceuticals, Inc. |
Methods of making ultra-high concentrated protein formulations using lyophilization
|
|
CN120623329A
(zh)
*
|
2025-01-15 |
2025-09-12 |
中国人民解放军军事科学院军事医学研究院 |
抗埃博拉病毒vp40蛋白的纳米抗体3e07及在病毒检测中的应用
|